3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Advanced Cancer
6
Melanoma
3
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Malignancies Multiple
1
Lymphoid Interstitial Pneumonia
1
Lung Neoplasms
1
Laryngeal Diseases
1
Head and Neck Neoplasms
1
Glioblastoma
1
Endometrial Adenocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Advanced Gastric Cancer
1
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
11
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
Radiotherapy
5
dodecyl maltoside
4
apaziquone
4
tislelizumab
3
Cystoscopy
3
ALT-803
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
5-aminolevulinic acid hexyl ester
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
monalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Non-Muscle Invasive Bladder Neoplasms
×
linrodostat
×
Clear all
NCT03519256
2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2
Terminated
142 enrolled
20 charts